When will Israeli biotech grow up?

Article Abstract:

Israel's creativity in the life sciences is doubtful, much of which comes from the country's seven major academic institutions, though investors are cautious of the apparent lack of ability to turn all the intellectual property into biotechnology products. The Israeli government and venture capitalists need to do more to fund biotech start-up companies in an effort to boost the country's biotech prospects, assert industry watchers.

Author: Katsnelson, Alla
Publisher: Nature Publishing Co.
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 2005
Israel, Drugs, Biotechnology industry, Biotechnology industries, Growth, Company growth

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA

Dow pulls out of bioplastics due to slow sector maturation

Article Abstract:

Chemical giant Dow declared that it was pulling out of a large investment in the agricultural and industrial company Minnesota-based Cargill since it might take longer than expected time to bring a return on investment. The joint venture between Cargill and Dow Chemical was set up to commercialize polyactic acid (PLA) under the brand name Nature Works.

Author: Katsnelson, Alla
Publisher: Nature Publishing Co.
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 2005
CHEMICALS AND ALLIED PRODUCTS, Plastics Materials and Synthetics, Company investment, Investments, Chemical industry, Dow Chemical Co. (Midland, Michigan), DOW, Pesticides industry, Herbicides, Synthetic fibers industry, Sulphur industry, Synthetic fibres industry, Cargill Dow L.L.C.

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA

First inhalable insulin approved

Article Abstract:

Exubera, the inhalable insulin made by Nektar Therapeutics, the San Francisco-based company is approved in both the United States and Europe in January 2006. Exubera offers diabetics an alternative to traditional needle-based delivery.

Author: Katsnelson, Alla
Publisher: Nature Publishing Co.
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 2006
Product development, Government regulation, Pharmaceutical preparations, Pharmaceutical industry, Licensing, certification and accreditation, Insulin, Nektar Therapeutics

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Subjects list: Finance, Company financing, United States
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.